• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Quality improvement project to enhance heparin safety in patients with haemodialysis in China.

作者信息

Tan Qiu-Zhen, Mai Yan-Fen, Jiao Hai-Hong, Xiong Ren-Jie, Liu Yu, Lin Li, Cui Li-Wen, Pai Pearl

机构信息

Department of Medicine, Division of Nephrology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

Clinical Service Department, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

出版信息

BMJ Open Qual. 2022 Apr;11(2). doi: 10.1136/bmjoq-2021-001665.

DOI:10.1136/bmjoq-2021-001665
PMID:35393293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8996018/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7d/8996018/3335498142e7/bmjoq-2021-001665f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7d/8996018/2deca0b26e98/bmjoq-2021-001665f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7d/8996018/3335498142e7/bmjoq-2021-001665f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7d/8996018/2deca0b26e98/bmjoq-2021-001665f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7d/8996018/3335498142e7/bmjoq-2021-001665f02.jpg

相似文献

1
Quality improvement project to enhance heparin safety in patients with haemodialysis in China.在中国开展的提高血液透析患者肝素使用安全性的质量改进项目。
BMJ Open Qual. 2022 Apr;11(2). doi: 10.1136/bmjoq-2021-001665.
2
Anti-heparin-platelet factor 4 antibodies are associated with arterial and venous thrombosis in patients with maintenance haemodialysis.抗肝素血小板因子4抗体与维持性血液透析患者的动脉和静脉血栓形成有关。
Thromb Haemost. 2009 Dec;102(6):1282-4. doi: 10.1160/TH09-05-0304.
3
Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis.肝素诱导抗体作为慢性血液透析患者发生血栓栓塞和出血的危险因素。
Lancet. 1996 Sep 14;348(9029):764. doi: 10.1016/s0140-6736(05)65684-x.
4
Review: anticoagulation for haemodialysis.综述：血液透析中的抗凝。
Nephrology (Carlton). 2010 Jun;15(4):386-92. doi: 10.1111/j.1440-1797.2010.01298.x.
5
[Heparin-induced thrombocytopenia syndrome and thrombosis in patients undergoing periodic haemodialysis].[定期血液透析患者的肝素诱导的血小板减少综合征与血栓形成]
G Ital Nefrol. 2002 Nov-Dec;19(6):672-92.
6
Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient.在肝素诱导的血小板减少症（HIT II）的常规血液透析中使用重组水蛭素进行抗凝。重组水蛭素在一名血液透析患者中的首次长期应用。
Wien Klin Wochenschr. 1997 May 23;109(10):354-8.
7
An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis.间歇性血液透析期间四种低剂量抗凝模式的评估
Eur J Clin Pharmacol. 2018 Mar;74(3):267-274. doi: 10.1007/s00228-017-2389-x. Epub 2017 Dec 2.
8
Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis.一名需要血液透析的患者因肝素诱导的血小板减少伴自发性血小板聚集而进行抗凝治疗。
Nephrol Dial Transplant. 1995 Nov;10(11):2137-40.
9
[Hypersensitive reaction after application of heparin with activation heparin induced trombocytopenia in initiation of intermittent haemodialysis].[应用肝素后发生超敏反应并激活肝素诱导的血小板减少症，用于间歇性血液透析起始阶段]
Vnitr Lek. 2015 Mar;61(3):260-63.
10
Haemodialysis-related-heparin-induced thrombocytopenia: Case series and literature review.血液透析相关肝素诱导的血小板减少症：病例系列及文献综述
Nefrologia (Engl Ed). 2018 Sep-Oct;38(5):551-557. doi: 10.1016/j.nefro.2018.02.010. Epub 2018 Jun 2.

本文引用的文献

1
Medication dose calculation errors and other numeracy mishaps in hospitals: Analysis of the nature and enablers of incident reports.医疗机构中的药物剂量计算错误和其他计算失误：对事件报告的性质和促成因素的分析。
J Adv Nurs. 2022 Jan;78(1):224-238. doi: 10.1111/jan.15072. Epub 2021 Oct 10.
2
Recent initiatives to enhance the safety of intravenous medications in Chinese hospitals.中国医院近期为提高静脉用药安全性所采取的举措。
Eur J Hosp Pharm. 2020 Nov;27(6):e101. doi: 10.1136/ejhpharm-2020-002412. Epub 2020 Aug 28.
3
Renal Association Clinical Practice Guideline on Haemodialysis.
英国肾脏病学会血液透析临床实践指南
BMC Nephrol. 2019 Oct 17;20(1):379. doi: 10.1186/s12882-019-1527-3.
4
Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis.低分子量肝素与普通肝素在血液透析中的安全性比较：一项系统评价和荟萃分析。
BMC Nephrol. 2017 Jun 7;18(1):187. doi: 10.1186/s12882-017-0596-4.
5
A Haemodialysis Journey from the West to the East.一段从西方到东方的血液透析历程。
Kidney Dis (Basel). 2016 Jun;2(2):88-94. doi: 10.1159/000444840. Epub 2016 Apr 1.
6
Anticoagulation in Chronic Hemodialysis: Progress Toward an Optimal Approach.慢性血液透析中的抗凝：迈向最佳方法的进展
Semin Dial. 2015 Sep-Oct;28(5):474-89. doi: 10.1111/sdi.12380. Epub 2015 Apr 25.
7
Maintaining safety in the dialysis facility.维持透析中心的安全。
Clin J Am Soc Nephrol. 2015 Apr 7;10(4):688-95. doi: 10.2215/CJN.08960914. Epub 2014 Nov 6.
8
Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study.中国北方城市血液透析患者抗凝治疗的现状及改进：一项为期五年的对比研究。
Chin Med J (Engl). 2014;127(16):2881-7.
9
Patient safety culture in China: a case study in an outpatient setting in Beijing.中国的患者安全文化：北京某门诊环境的案例研究。
BMJ Qual Saf. 2014 Jul;23(7):556-64. doi: 10.1136/bmjqs-2013-002172. Epub 2013 Dec 18.
10
Identifying, understanding and overcoming barriers to medication error reporting in hospitals: a focus group study.识别、理解和克服医院药物错误报告障碍：一项焦点小组研究。
BMJ Qual Saf. 2012 May;21(5):361-8. doi: 10.1136/bmjqs-2011-000299. Epub 2012 Mar 2.